Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
10 participants
INTERVENTIONAL
2024-08-22
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study design: A multiple-baseline single-case experimental design (SCED) across three time series. Participants will be randomized to one of the three time series. Within the time series the start of the intervention is randomly determined. Four participants will be assigned to the shortest, three to the medium and three to the longest baseline length. The SCED study consists of a baseline phase (A1), intervention phase (B), post-treatment phase (A2), follow-up phase 1 (A3), and follow-up phase 2 (A4).
Study population: Subjects are RA patients \> 18 years with low disease activity (DAS28\<3.2) at \>2 measurements over the previous 12 months and concurrent elevated pain scores (NRS-pain\>6).
Intervention (if applicable): EMDR therapy consists of an intake and eight sessions of 90 minutes in total, performed according to the EMDR standard protocol, conducted by four psychologists, all are level-II trained, under the supervision of an EMDR Europe consultant. EMDR focuses on processing traumatic memories, pain-related memories, and current physical pain.
Main study parameters/endpoints: Primary endpoint for effectiveness is the pre-treatment phase A1 to post-treatment phase A2 difference in NRS pain intensity. Feasibility is examined by monitoring recruitment, dropout rates, and treatment satisfaction. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: If the therapy is effective, pain intensity decreases, additional physical complaints of RA decrease and participants experience less discomfort from their pain in daily life. EMDR therapy is an evidence-based treatment for PTSD and the reduction of posttraumatic stress favors the recovery of physical complaints. Participating in the study includes two conversations for inclusion (two times 60 minutes consisting of one telephone conversation and one face-to-face conversation), attending the EMDR therapy intake (one time 90 minutes) and sessions (eight times 90 minutes), and daily registration of complaints (about two minutes per day) via a smartphone application, completing the questionnaires (about 14-28 minutes at six specific time points during the study), and an exit conversation at six months follow up. Daily registration will take 18 to 20 weeks maximum. At the three- and six-month follow-up, participants will be asked to register daily for 14 days. EMDR sessions can be emotionally intense, but never are as challenging as living with unprocessed (traumatic) pain-related memories. There are no risks associated with EMDR therapy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Shortest baseline length
Intervention starting points are at day 15, 16, 17, 18 or 19.
EMDR
Eye Movement Desensitization and Reprocessing
Medium baseline length
Intervention starting points are at day 20, 21, 22, 23, and 24.
EMDR
Eye Movement Desensitization and Reprocessing
Longest baseline length
Intervention starting points are at day 25, 26, 27, 28, or 29.
EMDR
Eye Movement Desensitization and Reprocessing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EMDR
Eye Movement Desensitization and Reprocessing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable low disease activity Score in 28 joints, i.e. DAS28 \<3.2 at \>2 measurements over the previous 12 months and at the time of inclusion
* Elevated pain scores (NRS pain \>6) at \>2 measurements over the previous 12 months and at the time of inclusion
* Sufficient knowledge of the Dutch language
Exclusion Criteria
* An acute suicidal risk
* Substance dependency
* Not stable on the use of medication
* Visual or hearing problems interfering with the EMDR procedure
* Other psychological/psychiatric treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Twente
OTHER
Leiden University Medical Center
OTHER
Medisch Spectrum Twente
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Harald E. Vonkeman
prof.dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medisch Spectrum Twente
Enschede, Overijssel, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMDR in RA
Identifier Type: -
Identifier Source: org_study_id